Dynamk Capital related stories
All articles and analysis
Vernal Biosciences picks up $21mVernal Biosciences, a technology-leading mRNA manufacturer and formulator of LNP-mRNA, has closed $21 million in financing.
Bionter AG procures $3mBionter AG, a Swiss provider of sub-visible particle testing, has raised $3 million in funding.
- Virica Biotech picks up Series A led by Dynamk Capital
Virica Biotech Inc., a developer of solutions for scaling of viral medicines, has closed its Series A funding round.
Envisagenics fetches Series AEnvisagenics, a developer of novel RNA splicing therapeutics, has secured an undisclosed amount of Series A funding.
- Lightspeed Microscopy reels in $4m Series A
Lightspeed Microscopy Inc, a 3D pathology platform, has raised $4 million in Series A financing.
- Dynamk Capital wraps up maiden life science fund
Dynamk Capital has closed its inaugural life science fund at $65 million.
- Curi Bio lands $6m Series A
Curi Bio Inc, a developer of human stem cell-based platforms for drug discovery, has raised $6 million in Series A financing.
- Lucid Scientific gathers $3m
Atlanta-based Lucid Scientific, a biotechnology tools company, has raised $3 million in funding.
- CellFE lands $4.8m
CellFE Inc, a developer of a microfluidics-based device to deliver gene-editing molecules, has raised $4.8 million in financing.
- CellFE grabs $3.6 mln
CellFE Inc, a developer of a microfluidics-based device to deliver gene-editing molecules, has raised $3.6 million in funding.